Table 1.
Evolution of the participants glycemia levels between baseline (T0) and after 2-month Cholesfytol NG® supplementation (T1) (N = 191).
| T0 glycemia | T1 glycemia | Glycemia absolute change | |||
|---|---|---|---|---|---|
| (mg/dL) | (mg/dL) | (mg/dL) | |||
| Glycemia levels (mg/dL) | N | Mean ± SD | Mean ± SD | Mean ± SD | p-value |
| ≥ 126 (T2DM) | 9 | 154 ± 25.8 | 111 ± 32.9 | −42.7 ± 17.9 | <0.0001 |
| 100–125 (prediabetic) | 51 | 107 ± 6.69 | 102 ± 11.8 | −2.26 ± 11.5 | 0.0020 |
| <100 (normal glycemia) | 131 | 88.3 ± 9.12 | 89.8 ± 9.24 | 1.55 ± 10.3 | 0.088 |
| Overall cohort | 191 | 96.4 ± 18.2 | 94.0 ± 13.5 | −2.35 ± 14.5 | 0.026 |